ChengDa Pharmaceuticals Co. Ltd. (301201) - Total Liabilities
Based on the latest financial reports, ChengDa Pharmaceuticals Co. Ltd. (301201) has total liabilities worth CN¥251.32 Million CNY (≈ $36.78 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ChengDa Pharmaceuticals Co. Ltd. (301201) asset resilience to evaluate the company's liquid asset resilience ratio.
ChengDa Pharmaceuticals Co. Ltd. - Total Liabilities Trend (2019–2025)
This chart illustrates how ChengDa Pharmaceuticals Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 301201 asset base.
ChengDa Pharmaceuticals Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of ChengDa Pharmaceuticals Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pexip Holding ASA
OL:PEXIP
|
Norway | Nkr508.69 Million |
|
Asseco Business Solutions S.A.
WAR:ABS
|
Poland | zł138.21 Million |
|
Ardmore Shpng
NYSE:ASC
|
USA | $154.39 Million |
|
HIVE Digital Technologies Ltd
NASDAQ:HIVE
|
USA | $109.79 Million |
|
Chenguang Biotech Group
SHE:300138
|
China | CN¥4.57 Billion |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
China | CN¥882.65 Million |
|
Sgis Songshan Co Ltd
SHE:000717
|
China | CN¥12.19 Billion |
|
Zhe Jiang Kangsheng Co Ltd
SHE:002418
|
China | CN¥1.62 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down ChengDa Pharmaceuticals Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ChengDa Pharmaceuticals Co. Ltd. balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ChengDa Pharmaceuticals Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ChengDa Pharmaceuticals Co. Ltd. (2019–2025)
The table below shows the annual total liabilities of ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥252.83 Million ≈ $37.00 Million |
-13.05% |
| 2024-12-31 | CN¥290.77 Million ≈ $42.55 Million |
+64.83% |
| 2023-12-31 | CN¥176.40 Million ≈ $25.81 Million |
+66.71% |
| 2022-12-31 | CN¥105.81 Million ≈ $15.48 Million |
-30.98% |
| 2021-12-31 | CN¥153.30 Million ≈ $22.43 Million |
+103.59% |
| 2020-12-31 | CN¥75.30 Million ≈ $11.02 Million |
-60.20% |
| 2019-12-31 | CN¥189.21 Million ≈ $27.69 Million |
-- |
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and A… Read more